https://ir.lenz-tx.com/ https://ir.lenz-tx.com/news-events/press-releases https://ir.lenz-tx.com/news-events/ir-calendar https://ir.lenz-tx.com/news-events/presentations https://ir.lenz-tx.com/news-events/email-alerts https://ir.lenz-tx.com/news-events/media https://ir.lenz-tx.com/company-information https://ir.lenz-tx.com/company-information/executive-team https://ir.lenz-tx.com/company-information/contacts https://ir.lenz-tx.com/company-information/faq https://ir.lenz-tx.com/financial-results https://ir.lenz-tx.com/stock-data/quote-chart https://ir.lenz-tx.com/stock-data/historical-data https://ir.lenz-tx.com/stock-data/analyst-coverage https://ir.lenz-tx.com/sec-filings https://ir.lenz-tx.com/corporate-governance https://ir.lenz-tx.com/corporate-governance/board-of-directors https://ir.lenz-tx.com/corporate-governance/board-committees https://ir.lenz-tx.com/corporate-governance/governance-documents https://ir.lenz-tx.com/news-events/press-releases/detail/52/lenz-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-highlights https://ir.lenz-tx.com/news-events/press-releases/detail/51/lenz-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-highlights-on-march-24-2026 https://ir.lenz-tx.com/news-events/press-releases/detail/50/lenz-therapeutics-announces-submission-of-marketing-authorization-application-to-european-medicines-agency-for-vizz-for-the-treatment-of-presbyopia https://ir.lenz-tx.com/news-events/press-releases/detail/49/lenz-therapeutics-to-present-at-upcoming-investor-conferences https://ir.lenz-tx.com/news-events/press-releases/detail/48/lenz-therapeutics-and-sarah-jessica-parker-announce-the-launch-of-make-it-vizzable-the-vizz-consumer-campaign https://ir.lenz-tx.com/news-events/press-releases/detail/47/lenz-therapeutics-reports-fourth-quarter-2025-preliminary-unaudited-financial-results-and-recent-corporate-updates https://ir.lenz-tx.com/news-events/press-releases/detail/46/lenz-therapeutics-and-lunatus-announce-exclusive-commercialization-partnership-for-vizzin-the-middle-east https://ir.lenz-tx.com/news-events/press-releases/detail/45/lenz-therapeutics-announces-mfds-submission-of-new-drug-application-for-lnz100-vizz-in-south-korea-for-the-treatment-of-presbyopia https://ir.lenz-tx.com/news-events/press-releases/detail/44/lenz-therapeutics-to-present-at-upcoming-investor-conferences https://ir.lenz-tx.com/news-events/press-releases/detail/43/lenz-therapeutics-reports-third-quarter-2025-financial-results-and-recent-corporate-highlights https://ir.lenz-tx.com/news-events/press-releases/detail/42/lenz-therapeutics-to-report-third-quarter-2025-financial-results-and-recent-corporate-highlights-on-november-5-2025 https://ir.lenz-tx.com/news-events/press-releases/detail/41/lenz-therapeutics-announces-commercial-product-availability-of-vizzin-the-united-states https://ir.lenz-tx.com/news-events/press-releases/detail/40/lenz-therapeutics-to-present-at-upcoming-investor-and-medical-conferences https://ir.lenz-tx.com/news-events/press-releases/detail/39/lenz-therapeutics-announces-us-fda-approval-of-vizz-for-the-treatment-of-presbyopia https://ir.lenz-tx.com/news-events/press-releases/detail/38/lenz-therapeutics-reports-second-quarter-2025-financial-results-and-recent-corporate-highlights https://ir.lenz-tx.com/news-events/press-releases/detail/37/lenz-therapeutics-announces-nmpa-submission-of-new-drug-application-for-lnz100-in-china-for-the-treatment-of-presbyopia https://ir.lenz-tx.com/news-events/press-releases/detail/36/lenz-therapeutics-and-laboratoires-tha-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada https://ir.lenz-tx.com/news-events/press-releases/detail/35/lenz-therapeutics-to-present-at-upcoming-investor-conferences https://ir.lenz-tx.com/news-events/press-releases/detail/34/lenz-therapeutics-and-lotus-pharmaceutical-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-the-republic-of-korea-and-southeast-asia https://ir.lenz-tx.com/news-events/press-releases/detail/33/lenz-therapeutics-reports-first-quarter-2025-financial-results-and-recent-corporate-highlights https://ir.lenz-tx.com/news-events/press-releases/detail/32/lenz-therapeutics-to-participate-in-upcoming-bofa-securities-2025-health-care-conference https://ir.lenz-tx.com/news-events/press-releases/detail/31/lenz-therapeutics-to-report-first-quarter-2025-financial-results-and-recent-corporate-highlights-on-may-7th-2025 https://ir.lenz-tx.com/news-events/press-releases/detail/30/lenz-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-corporate-highlights https://ir.lenz-tx.com/news-events/press-releases/detail/29/lenz-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-and-recent-corporate-highlights-on-march-19-2025 https://ir.lenz-tx.com/news-events/press-releases/detail/28/lenz-therapeutics-to-host-commercial-day-on-april-15-2025 https://ir.lenz-tx.com/news-events/press-releases/detail/27/lenz-therapeutics-to-participate-in-upcoming-investor-conferences https://ir.lenz-tx.com/news-events/press-releases/detail/26/lenz-therapeutics-to-participate-in-upcoming-investor-conferences https://ir.lenz-tx.com/news-events/press-releases/detail/25/lenz-therapeutics-reports-third-quarter-2024-financial-results https://ir.lenz-tx.com/news-events/press-releases/detail/24/lenz-therapeutics-to-report-third-quarter-financial-results-and-business-update-on-november-6-2024 https://ir.lenz-tx.com/news-events/press-releases/detail/23/corxel-and-lenz-therapeutics-announce-positive-topline-data-from-china-phase-3-presbyopia-trial-of-lnz100 https://ir.lenz-tx.com/news-events/press-releases/detail/22/lenz-therapeutics-announces-fda-acceptance-of-new-drug-application-for-lnz100-for-the-treatment-of-presbyopia https://ir.lenz-tx.com/news-events/press-releases/detail/21/lenz-therapeutics-announces-presentations-at-upcoming-ophthalmology-and-optometry-medical-conferences https://ir.lenz-tx.com/news-events/press-releases/detail/20/lenz-therapeutics-to-participate-in-upcoming-investor-conferences https://ir.lenz-tx.com/news-events/press-releases/detail/19/lenz-therapeutics-reports-second-quarter-2024-financial-results https://ir.lenz-tx.com/news-events/press-releases/detail/18/lenz-therapeutics-announces-submission-of-new-drug-application-to-u-s-food-and-drug-administration-for-lnz100-for-the-treatment-of-presbyopia https://ir.lenz-tx.com/news-events/press-releases/detail/17/lenz-therapeutics-to-report-second-quarter-2024-financial-results-on-august-14-2024 https://ir.lenz-tx.com/news-events/press-releases/detail/16/lenz-therapeutics-announces-30-million-investment-from-ridgeback-capital https://ir.lenz-tx.com/news-events/press-releases/detail/15/lenz-therapeutics-to-host-key-opinion-leader-event-on-june-18-2024 https://ir.lenz-tx.com/news-events/press-releases/detail/14/lenz-therapeutics-to-present-at-the-jefferies-global-healthcare-conference https://ir.lenz-tx.com/news-events/press-releases/detail/13/lenz-therapeutics-reports-first-quarter-2024-financial-results-and-provides-business-updates https://ir.lenz-tx.com/news-events/press-releases/detail/12/lenz-therapeutics-to-report-first-quarter-financial-results-and-business-update-on-may-8-2024 https://ir.lenz-tx.com/news-events/press-releases/detail/11/lenz-therapeutics-announces-positive-topline-data-from-phase-3-clarity-presbyopia-trials https://ir.lenz-tx.com/news-events/press-releases/detail/10/lenz-therapeutics-to-host-investor-call-to-discuss-topline-results-from-the-phase-3-clarity-presbyopia-trials https://ir.lenz-tx.com/news-events/press-releases/detail/9/lenz-therapeutics-announces-completion-of-merger-with-graphite-bio-and-provides-update-on-recent-clinical-and-corporate-progress https://ir.lenz-tx.com/news-events/press-releases/detail/5/lenz-therapeutics-announces-83-5-million-series-b-financing-to-advance-its-presbyopia-treatments-lnz100-and-lnz101-and-provides-update-on-ongoing-phase-3-studies https://ir.lenz-tx.com/news-events/press-releases/detail/6/lenz-therapeutics-announces-positive-topline-data-from-phase-2-insight-trial-of-lnz100-and-lnz101-to-treat-presbyopia https://ir.lenz-tx.com/news-events/press-releases/detail/7/lenz-therapeutics-and-jixing-announce-an-exclusive-greater-china-license-agreement-rtw-to-invest-in-lenz-therapeutics https://ir.lenz-tx.com/news-events/press-releases/detail/8/lenz-therapeutics-debuts-with-47-million-series-a-financing https://ir.lenz-tx.com/privacy-policy https://ir.lenz-tx.com/disclaimer https://ir.lenz-tx.com/sitemap https://ir.lenz-tx.com/accessibility-statement